Jefferies analyst Tycho Peterson assumed coverage of Exact Sciences with a Buy rating and price target of $75, down from $85. The firm believes “durable growth stories” in the life sciences and diagnostic tools group with operating leverage, healthy free cash flow and balance sheet optionality “should be rewarded.” The analyst sees a host of headwinds for growth tools and awaits more visibility, and is upbeat on the secular growth drivers in the diagnostics space. Recent survey works points to muted next generation sequencing and proteomics budgets, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Craig-Hallum would be buyers of Exact Sciences amid weakness
- Exact Sciences to present new data on screening and diagnostic portfolio at ASCO
- Court denies Geneoscopy motion to dismiss Exact Sciences suit, says Guggenheim
- Exact Sciences allowed by court to proceed with lawsuit against Geneoscopy
- Exact Sciences price target lowered to $80 from $85 at BTIG